Short answer
SBC Medical Group Holdings Inc (SBC) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $59M (up 35.1% year over year) with net income of $16M.
Q3 2026 key financials · XBRL
- Revenue
- $59M
- +35.1% YoY · +19.1% QoQ
- Net income
- $16M
- +22.4% YoY · +46.8% QoQ
- Operating margin
- 45.1%
- Gross margin
- 72.0%
- EPS (diluted)
- $0.16
- +23.1% YoY · +60.0% QoQ
Source: XBRL data from the SBC Medical Group Holdings Inc (SBC) Q3 2026 10-Q on SEC EDGAR. USD.
SBC Medical Group Holdings Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $58.6M, up 35.13% YoY from $43.4M
- Operating margin 45.09% vs 36.63% YoY, net income margin 26.79% vs 29.58%
- Best line management services revenue $16.4M, up 73.28%; weakest franchising revenue $9.6M, down 3.60%
- Cash $198.4M vs $163.8M at December 31, 2025; operating cash flow $50.2M vs $(27.3)M
- Capital deployment: $8.9M borrowing repayments, $5.0M investment commitment, no share repurchases under $20.0M authorization
Risk Factors
- New Nasdaq compliance risk: independent director departure triggered board and audit committee violations on July 8, 2026
- Most material update: delisting risk, Nasdaq cure period runs through July 9, 2027
- Regulatory risk: delisting could reduce liquidity and classify common stock as a penny stock
- Operational risk: failure to appoint independent directors could prevent restored Nasdaq compliance
- Financial risk: delisting could decrease ability to issue securities or obtain future financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SBC Medical Group Holdings Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.